The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Pharmacokinetic and safety profile of trans‐resveratrol in a rising multiple‐dose study in healthy volunteers
Abstract
This was a double‐blind, randomised, placebo‐controlled study to investigate the pharmacokinetics and safety of trans‐resveratrol. In four groups of ten healthy adult subjects (five males and five females), two subjects were randomized to receive placebo and eight subjects to receive trans‐resveratrol 25, 50, 100 or 150 mg, six times/day, for thirteen doses. Peak plasma concentrations of trans‐resveratrol were reached at 0.8–1.5 h postdose. Following the 13th dose of trans‐resveratrol 25, 50, 100 and 150 mg, mean peak plasma concentration (Cmax) was 3.89, 7.39, 23.1 and 63.8 ng/mL and mean area under the plasma concentration–time curve (AUC 0‐τ) was 3.1, 11.2, 33.0 and 78.9 ng·h/mL. Interindividual variability was high, with coefficients of variation >40%.Trans‐resveratrol half‐life was 1–3 h following single‐doses and 2–5 h following repeated dosing. Trough (Cmin) concentrations were ⪇1 ng/mL following 25 and 50 mg, 3 ng/mL following 100 mg and < 10 ng/mL following 150 mg.Trans‐resveratrol pharmacokinetics showed circadian variation. Adverse events were mild in severity and similar between all groups. In conclusion, repeated administration was well‐tolerated but produced relatively low plasma concentrations of trans‐resveratrol, despite the high doses and short dosing interval used. Bioavailability was higher after morning administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS
Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., & Walle, U. K. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000885 · Cited by 1,880
Biological effects of resveratrol
Frémont, L. (2000) · Life Sciences · doi:10.1016/s0024-3205(99)00410-5 · Cited by 1,663
Boocock, D. J., Faust, G. E. S., Patel, K. R., Schinas, A. M., Brown, V. A., Ducharme, M. P., Booth, T. D., Crowell, J. A., Perloff, M., Gescher, A. J., et al. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0022 · Cited by 824
Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications
Alarcón de la Lastra, C., & Villegas, I. (2005) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200500022 · Cited by 703
Metabolism and bioavailability oftrans-resveratrol
Wenzel, E., & Somoza, V. (2005) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200500010 · Cited by 676
Biological Effects of Resveratrol
Bhat, K. P. L., Kosmeder, J. W., & Pezzuto, J. M. (2001) · Antioxidants & Redox Signaling · doi:10.1089/152308601317203567 · Cited by 507
Marier, J.-F., Vachon, P., Gritsas, A., Zhang, J., Moreau, J.-P., & Ducharme, M. P. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033340 · Cited by 480
Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer
Delmas, D., Lancon, A., Colin, D., Jannin, B., & Latruffe, N. (2006) · Current Drug Targets · doi:10.2174/138945006776359331 · Cited by 395
Kopp, P. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1380619 · Cited by 392
Resveratrol—A boon for treating Alzheimer's disease?
Anekonda, T. S. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.04.004 · Cited by 339
Aziz, M., Kumar, R., & Ahmad, N. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.1.17 · Cited by 316
Bioavailability oftrans-resveratrol from red wine in humans
Vitaglione, P., Sforza, S., Galaverna, G., Ghidini, C., Caporaso, N., Vescovi, P. P., Fogliano, V., & Marchelli, R. (2005) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200500002 · Cited by 313
Kumar, A., Kaundal, R. K., Iyer, S., & Sharma, S. S. (2007) · Life Sciences · doi:10.1016/j.lfs.2006.12.036 · Cited by 196
Potential Mechanism by Which Resveratrol, a Red Wine Constituent, Protects Neurons
ZHUANG, H., KIM, Y., KOEHLER, R. C., & DORÉ, S. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07534.x · Cited by 186
Burkon, A., & Somoza, V. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700290 · Cited by 180
Soleas, G. J., Yan, J., & Goldberg, D. M. (2001) · Journal of Chromatography B: Biomedical Sciences and Applications · doi:10.1016/s0378-4347(01)00142-6 · Cited by 166
Chronopharmacokinetics: Current Status
Bruguerolle, B. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835020-00001 · Cited by 158
Resveratrol and Cancer: Chemoprevention, Apoptosis, and Chemoimmunosensitizing Activities
Cal, C., Garbán, H., Jazirehi, A. R., Yeh, C.-H., Mizutani, Y., & Bonavida, B. (2003) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011033353443 · Cited by 152
Wang, L., Heredia, A., Song, H., Zhang, Z., Yu, B., Davis, C. E. L. B., & Redfield, R. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20156 · Cited by 129
Effect of food on the pharmacokinetic profile of trans-resveratrol
Vaz‐da‐Silva, M., Loureiro, A. I., Falcão, A. C., Nunes, T., Rocha, J.-F., Fernandes‐Lopes, C., Soares, E., Wright, L. C., Almeida, L., & Soares-da-Silva, P. (2008) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp46564 · Cited by 105
Self-citationBlardi, P., Lalla, A. D., Volpi, L., & Perri, T. D. (1999) · PubMed · Cited by 22
Cited by
Del Rio, D., Rodriguez-Mateos, A., Spencer, J. P. E., Tognolini, M., Borges, G., & Crozier, A. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4581 · Cited by 2,601
“Gastric absorption explains the peak of free resveratrol in the plasma 30 min after ingestion (8, 39, 475, 479).”
Antioxidant Phytochemicals for the Prevention and Treatment of Chronic Diseases
Zhang, Y.-J., Gan, R.-Y., Li, S., Zhou, Y., Li, A.-N., Xu, D.-P., & Li, H.-B. (2015) · Molecules · doi:10.3390/molecules201219753 · Cited by 1,369
Bioavailability of resveratrol
Walle, T. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05842.x · Cited by 1,051
Polyphenols and Human Health: Prevention of Disease and Mechanisms of Action
Vauzour, D., Rodriguez-Mateos, A., Corona, G., Oruna-Concha, M. J., & Spencer, J. P. E. (2010) · Nutrients · doi:10.3390/nu2111106 · Cited by 855
Gambini, J., Inglés, M., Olaso, G., Lopez-Grueso, R., Bonet-Costa, V., Gimeno-Mallench, L., Mas-Bargues, C., Abdelaziz, K. M., Gomez-Cabrera, M. C., Vina, J., et al. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/837042 · Cited by 737
Metadata
- Authors
- Almeida, L., Vaz‐da‐Silva, M., Falcão, A., Soares, E., Costa, R., Loureiro, A. I., Fernandes‐Lopes, C., Rocha, J., Nunes, T., Wright, L., & Soares‐da‐Silva, P.
- Venue
- Molecular Nutrition & Food Research
- Publisher
- Wiley
- Published
- 2009-05
- Volume
- 53
- Issue
- S1
- Pages
- S7-15
- ISSN
- 1613-4125 (ISSN-L)
- 1613-4133
- OpenAlex
- W2051990086
- Cited by
- 426
- References
- 21
- FWCI
- 16.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.